NCT03361748 · OUTCOME

Duration of Response

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: From first dose to 24 months after first dose

What was measured

Time from first documentation of response or PR or better to first documentation of disease progression or death from any cause, whichever occurs first.

Analysis population: All Treated Participants with a CR or PR as per IRC

Groups in this outcome

BB2121

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
BB2121	102

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
BB2121	11.04	Not reported	9.92	12.52	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
9.92
upper Limit
12.52
value
11.04

denoms

counts
group Id
OG000
value
102
units
Participants

description

Time from first documentation of response or PR or better to first documentation of disease progression or death from any cause, whichever occurs first.

dispersion Type

95% Confidence Interval

groups

description
BB2121
id
OG000
title
BB2121

param Type

MEDIAN

population Description

All Treated Participants with a CR or PR as per IRC

reporting Status

POSTED

time Frame

From first dose to 24 months after first dose

title

Duration of Response

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice